Furthermore, it can be utilized in the development of CD19-CD3 bispecific antibodies, enhancing the specificity of T cell-mediated tumor cell killing, in line with strategies used for human bispecific antibodies, while also demonstrating significant potential for precise detection and targeted therapy of T-cell lymphoma, as well as exhibiting promising applications in the treatment of autoimmune diseases (11–13). The gene discussed is CD19; the disease is T-cell non-Hodgkin lymphoma.